Abstract
Coronary artery bypass graft (CABG) surgery remains the gold standard in the treatment of complex coronary artery disease. Saphenous vein grafts (SVG) are commonly used for the non-left anterior descending artery. However, SVG failure rates in CABG surgery have been reported to be as high as 30% at 1 year and ∼50% at 10 years. Despite suboptimal performance, ∼80% of all CABG surgery includes SVG graft use. Therefore, an off-the-shelf, small-diameter vascular conduit with good patency rates remains a large unmet clinical need. XABG (Xeltis BV, Eindhoven, The Netherlands), a novel supramolecular electrospun biorestorative polymeric conduit with an embedded nitinol microskeleton, is under clinical development to fulfill this unmet need. This case report aims to demonstrate the safety and feasibility of this conduit in a routine CABG operation with implantation in a 70-year-old male patient with three-vessel disease. The XABG conduit remained patent with TIMI 3 flow at 6 months, and patency was confirmed by cardiac computed tomography at 12 months.